Alzheimer's disease (AD) is a disorder that causes degeneration of the cells in the brain and
it is the main cause of dementia, which is characterized by a decline in thinking and …

Dementia is increasingly being recognized as one of the most important medical problems
in the elderly. As most pharmacological research within the field of dementia is focused on …

The pathophysiology of Alzheimer's disease (AD) includes the deposition of amyloid beta
protein (Abeta) and the ensuing initiation of a variety of secondary processes, including tau …

Novel agents addressing non-amyloid, non-tau targets in Alzheimer's Disease (AD)
comprise 70% of the AD drug development pipeline of agents currently in clinical trials. Most …

The transition from either epidemiological observation or the bench to rigorously tested
clinical trials in patients with Alzheimer's disease is crucial in understanding which …

Alzheimer's disease (AD) is a devastating neurological disorder that affects more than 37
million people worldwide1. The economic burden of AD is massive; in the United States …

Alzheimer's disease (AD) is the most common form of dementia characterized by presence
of extracellular amyloid plaques and intracellular neurofibrillary tangles composed of tau …

Alzheimer's disease (AD) stands as the predominant form of dementia, presenting significant
and escalating global challenges. Its etiology is intricate and diverse, stemming from a …

The amyloid β (Aβ) and tau proteins, which misfold, aggregate, and accumulate in the
Alzheimer's disease (AD) brain, are implicated as central factors in a complex …

Alzheimer's disease (AD) is characterized histopathologically by numerous neurons with
neurofibrillary tangles and neuritic (senile) amyloid-β (Aβ) plaques, and clinically by …